November 15, 2017- Assessing User Fees Under the Biosimilar User Fee Amendments of 2017 Guidance for Industry (PDF - 359KB)
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)
- FDA Drug Shortages
- Amino Acids (Updated - Currently in Shortage)
- Lamisil Tablets (New - Discontinuation)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated - Currently in Shortage)
- National Drug Code Directory (updated)
- Wholesale Distributor and Third-Party Logistics Providers Reporting (updated)
.png)
No hay comentarios:
Publicar un comentario